Stephen R Marder, M.D.

 

Stephen R Marder, M.D.
Daniel X. Freedman Professor of Psychiatry
Vice Chair for Education, Semel Institute for Neuroscience
University of California, Los Angeles
Director, VA Desert Pacific Mental Illness Research, Education, and Clinical Center, Los Angeles


Presentation: Looking Beyond Psychosis, Addressing Negative Symptoms in Schizophrenia


Bio:

Stephen R. Marder, M.D. is the Daniel X. Freedman Professor of Psychiatry, the Vice Chair for Education, and the Director of the Section on Psychosis at the UCLA Semel  Institute for Neuroscience and Human Behavior.  He is also the Director of the VISN 22 Mental Illness Research, Education Clinical Center (MIRECC) for the Department of Veterans Affairs.

Dr. Marder received his AB from the University of Pennsylvania and his MD from the State University of New York in Buffalo.   He completed an Internship at Denver General Hospital and a Psychiatry Residency at the University of Southern California.   This was followed by two years of research training at the National Institute of Mental Health (NIMH) Clinical Center.

Dr. Marder’s research has focused on improving the lives of individuals with psychotic disorders, particularly schizophrenia.   His research —  supported by the VA, the Brain and Behavior Research Foundation, and the National Institute of Mental Health — has focused on the development of pharmacological,  psychosocial, and rehabilitation approaches for improving functioning and quality of life.  He led the NIMH MATRICS (Management and Treatment Research to Improve Cognition in Schizophrenia) initiative which provided guidance for the development of pharmacologic agents to improve cognition and motivation in schizophrenia.  He also led an NIMH Network for trials of medications for improving cognition in schizophrenia.   From 2016 to 2018 he was the President of the International Society of CNS Clinical Trials and Methodology.   He is considered an expert on clinical trials methods for complex CNS disorders, particularly schizophrenia.

Dr. Marder has received the Exemplary Psychiatrist Award from the National Alliance for the Mentally Ill, the Stanley Dean Research Award of the American College of Psychiatry, the Alexander Gralnick Award from the American Psychiatric Association, the Kempf Award from the American Psychiatric Association, the American Psychiatric Association Award for Research, the Wayne Fenton Award for Outstanding Clinical Care from the Schizophrenia Bulletin, and the Lieber Prize for Schizophrenia Research.  He is listed in The Best Doctors in America and America’s Top Doctors.


Disclosure: Dr. Marder has the following relevant financial relationships, potential or perceived, with commercial or conflicts of interest to disclose:

  • Grant / Research Support: Boeringer Ingelheim, Takeda, Neurocrine
  • Consultant: Lundbeck, Otsuka, Merck, Teva, Allergan

Review of Conflicts Policy:  The UT Austin College of Pharmacy has a very strict policy to ensure against commercial conflicts of interest in CE programming.  For this conference, the planning committee picks two committee members who have appropriate backgrounds to review content, and report any potential conflict of interest to the CPE Director.  If conflict issues are discovered, they are addressed with speakers to make appropriate changes. Evaluations are collected from all participants with specific questions around the listed conflicts of commercial interest.